An Observational Study Of Indian Breast Cancer Patients Receiving Adjuvant Therapy With Aromasin

Overview

To generate the following data from patients with early breast cancer treated with Aromasin® in the adjuvant setting in India. – Efficacy of the treatment with Aromasin® – Safety of the treatment with Aromasin®

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 2012

Detailed Description

NA The study was prematurely discontinued due to slow enrollment and keeping in mind the observational nature of the study. The decision to terminate had been taken on 16th June 2012 and the LSLV occured on 14th September, 2012. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.

Interventions

  • Other: Aromasin
    • Non-Interventional study design.

Arms, Groups and Cohorts

  • Observational

Clinical Trial Outcome Measures

Primary Measures

  • Number of Participants With Locoregional/Distant Recurrence of Primary Breast Cancer
    • Time Frame: Baseline until locoregional/distant recurrence of primary breast cancer (up to Year 3.5)
    • Locoregional recurrence was defined as any recurrence of the breast cancer in the ipsilateral breast, chest wall or axillary lymph nodes.
  • Number of Participants With Appearance of Second Primary or Contralateral Breast Cancer
    • Time Frame: Baseline until appearance of second primary or contralateral breast cancer (up to Year 3.5)
  • Number of Participants Who Died
    • Time Frame: Baseline until death (up to Year 3.5)
  • Number of Participants Who Discontinued Aromasin Therapy
    • Time Frame: Baseline until discontinuation (up to Year 3.5)
  • Number of Participants With Gynecological, Cardiac, Thromboembolic, Musculoskeletal and Menopausal Adverse Events (AEs)
    • Time Frame: Baseline up to 28 days after last dose of study treatment
    • An AE was any untoward medical occurrence in participant who received study drug without regard to possibility of causal relationship. Number of participants with AEs related to gynecological, cardiac, venous thromboembolic, musculoskeletal and menopausal symptoms were reported. Gynecological AEs: bleeding, discharge, uterine dilatation and curettage; cardiac AEs: myocardial infarction, hypertension; musculoskeletal: joint stiffness, arthralgia, muscle cramps, fractures; menopausal symptoms: hot flushes, anxiety, depression, headache.
  • Change From Baseline in High Density Lipoprotein-Cholesterol (HDL-C), Low Density Lipoprotein-Cholesterol (LDL-C), Total Cholesterol and Triglycerides at Month 6, 12, 18, 24, 30, 36 and 42
    • Time Frame: Baseline, Month 6, 12, 18, 24, 30, 36, 42
  • Change From Baseline in Bone Mineral Density (BMD) at Month 6, 12, 18, 24, 30, 36 and 42
    • Time Frame: Baseline, Month 6, 12, 18, 24, 30, 36, 42

Participating in This Clinical Trial

Inclusion Criteria

  • Patients with early breast cancer receiving adjuvant therapy with Aromasin® will be eligible. Exclusion Criteria:

  • Patients presenting with in situ cancers, recurrent or metastatic breast cancer, or a 2nd primary will not be included. – Patients with a known hypersensitivity to Exemestane or its metabolites will also not be included.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Pfizer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pfizer CT.gov Call Center, Study Director, Pfizer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.